What Are Bayer's M&A Opportunities?

July 16 (Bloomberg) -- Bloomberg Industries' Sam Fazeli examines M&A opportunities for Bayer, moves in the overall pharmaceutical market and the Chinese government's probe into Glaxo Smithkline. He speaks on Bloomberg Television's "The Pulse."

Teva Said Close to Closing $40.5 Billion Allergan Deal
20:22 - The U.S. Federal Trade Commission is close to signing off on Teva Pharmaceutical's deal to buy Allergan Plc's generics unit for $40.5 billion according to people familiar with the matter. Bloomberg's Elliot Gotkine reports on "Bloomberg Markets Middle East." (Source: Bloomberg)
  • Bracing for Yet Another Global Banking Crisis
  • Brexit Brews Trouble for SABMiller-AB InBev Deal
  • Ford CEO: Brexit and Lower Pound Hurt Us